Genetically engineered immune cells show promise for fighting relapsed blood cancer
Tuesday, December 4, 2018 - 00:30
in Health & Medicine
Researchers are presenting preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.